4,712 Shares in Repligen Corporation $RGEN Bought by Callan Family Office LLC

Callan Family Office LLC acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,712 shares of the biotechnology company’s stock, valued at approximately $643,000.

A number of other large investors have also made changes to their positions in the stock. Avidity Partners Management LP lifted its position in shares of Repligen by 54.7% in the 1st quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock worth $9,166,000 after acquiring an additional 27,500 shares during the period. Swedbank AB bought a new stake in shares of Repligen during the fourth quarter valued at approximately $4,146,000. B. Metzler seel. Sohn & Co. AG bought a new stake in shares of Repligen during the second quarter valued at approximately $3,597,000. Global Retirement Partners LLC acquired a new position in shares of Repligen in the second quarter valued at $655,000. Finally, Conestoga Capital Advisors LLC raised its stake in shares of Repligen by 10.6% in the fourth quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock valued at $173,360,000 after purchasing an additional 101,062 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on RGEN. Jefferies Financial Group reiterated a “hold” rating and set a $142.00 price target on shares of Repligen in a research note on Tuesday, May 5th. Citigroup upgraded shares of Repligen to a “buy” rating in a research note on Tuesday, July 7th. Evercore restated an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th. Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Finally, Wolfe Research initiated coverage on shares of Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $166.43.

Repligen Price Performance

Repligen stock opened at $181.69 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The company has a market capitalization of $10.25 billion, a PE ratio of 248.89, a price-to-earnings-growth ratio of 3.31 and a beta of 1.03. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73. The business has a 50 day simple moving average of $149.17 and a 200 day simple moving average of $132.22.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same quarter in the previous year, the firm earned $0.26 EPS. Repligen’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts forecast that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.